• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    B

    Bendigo Health

    EST. 1853
    573论文总数
    6,150引用总数

    论文量&引用量时间轴

    机构学者

    论文(573)

    年份
    起
    –
    止
    排序
    1Total Versus Subtotal Gastrectomy Following Neoadjuvant Flot Chemotherapy for Distal Diffuse Gastric Adenocarcinoma: an International Cohort Study
    Jonathan Sivakumar, Darren J. Wong, Katheryn Hall, Margaret M. Lee, Cuong P. Duong, David I. Watson,Claire L. Donohoe,Tim Bright,Ahmad Aly, Kevin Chan,David L. Chan, Neil Merrett,

    To compare perioperative, oncological, and survival outcomes of total gastrectomy (TG) versus subtotal gastrectomy (SG) in patients with locally advanced distal diffuse gastric adenocarcinoma treated with perioperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy. Diffuse distal gastric cancer is characterized by infiltrative growth patterns and early nodal metastasis. Whilst radical resection remains the cornerstone of curative treatment, the optimal extent of surgery with TG or SG, remains debated. This international multicenter cohort study analyzed data from patients with histologically confirmed diffuse gastric adenocarcinoma, located > 5 cm from the gastroesophageal junction. Endpoints included surgical margin status, nodal yield, perioperative morbidity, recurrence patterns, time-to-recurrence (TTR), and overall survival (OS). Outcomes were compared using multivariate analyses. In total, 188 (39.0

    2026Gastric Cancer(2026)引用:32
    引用
    AI阅读
    加入学术空间
    2Real World Evidence of Systemic Therapy in Hormone Receptor Positive Advanced Breast Cancer (HR Plus ABC) in Australia - ARORA Registry
    M. Li,V Wong,S. Baron-Hay, R. de Boer,F. Boyle, A. Campbell,I. M. Collins,K. Cuff,L. Gately,C. Georgiou,S. Greenberg, E. Jude,

    e13054 Background: The last decade has seen a rapid increase in systemic treatment options for patients with HR+ ABC. The incorporation of CDK4/6 inhibitors in first line (1L) is now standard practice leading to improved survival. However, there is a paucity of data on uptake of standard therapies and associated toxicities in the real-world setting. Methods: ARORA is a secondary data use study of Australian patients with HR+ ABC capturing prospective data on patient characteristics, systemic therapy sequencing and treatment outcomes in routine clinical practice. Patients aged > 18 diagnosed after 1 Jan 2020 are eligible. Results: Data from 294 patients at 16 sites was analysed with a median follow up of 15 months. Mean age was 63 years; 23% > 75 years. 64% were ECOG 0, 5.4% had a familial syndrome, 61% had relapsed metastatic disease and 19.4% had bone only metastases at diagnosis. Of patients who relapsed, 14.6% and 52.8% received neoadjuvant and adjuvant chemotherapy respectively, and 77.5% received adjuvant endocrine therapy (ET). 41% relapsed on or within 12 months of stopping adjuvant ET. 5 patients (1.7%) did not receive any systemic therapy for ABC. Of those on 1L therapy, 223 (77%) received CDK4/6i + ET, 38 (13.1%) received ET alone and 26 (9%) received chemotherapy. Choice of 1L CDK4/6i was palbociclib (50.7%), ribociclib (34.5%) and abemaciclib (9.9%). Patients who received 1L ET alone were older (mean age 75 vs 62 years; 68.4 vs 16.6% > 75 years) with poorer performance status (34.2 vs 6.3% ECOG ≥2) and more comorbidities (76.3 vs 36.8% Charlson index > 2) compared to those who received 1L CDK4/6i + ET. Conversely, those on 1L chemotherapy were younger (mean age 54, 96.2% < 75years), with better performance status (69.2% ECOG 0-1) and fewer comorbidities (88.5% Charlson index < 2). Patients receiving 1L chemotherapy were more likely to have visceral metastases compared to those on CDK4/6i + ET (69.2 vs 43.1%, p = 0.01). The most common reported toxicities in patients receiving CDK4/6i were diarrhea (59% abemaciclib vs 3.9% ribociclib vs 2.7% palbociclib), neutropenia (38.1% palbociclib vs 32.5% ribociclib vs 22.7% abemaciclib) and nausea/vomiting (27.3% abemaciclib vs 22.1% ribociclib vs 12.4% palbociclib). Abnormal LFTs occurred in 9.1% of patients on abemaciclib (vs 3.9% ribociclib and < 1% palbociclib). 2 patients (1.8%) on palbociclib had pneumonitis whilst 1 (1.3%) on ribociclib had QTc prolongation. Survival data is immature. Conclusions: Despite CDK4/6i + ET being gold standard treatment in 1L HR+ ABC, only 3/4 of patients received this combination, with a substantial minority receiving ET alone or chemotherapy. Age, ECOG status, comorbidity burden and presence of visceral disease appear to be major determinants of treatment choice. Toxicity profile of the CDK4/6i agents were mostly in line with clinical trial results, although longer follow up is needed to confirm this.

    2026CLINICAL CANCER RESEARCH(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Lessons Learned from a Victorian Regional Allied Health Professional and Workforce Support Project.
    Sarah Gallagher,Marcus Gardner

    PROBLEM:Accessing professional support such as professional development, clinical supervision and peer support can be difficult for rural and regional allied health (AH) clinicians and may have a negative impact on workforce recruitment and retention. SETTING:The Loddon Mallee Health Network, a Health Service Partnership of 19 health services in North-Western Victoria. Professions included were AH therapy professions. KEY MEASURES FOR IMPROVEMENT:Five professional support and workforce capacity building strategies were implemented, relating to clinical supervision, building capacity to provide student placements, professional development, graduate support and building AH clinical educator capacity. Program logic was used as the overarching methodology to evaluate the implementation of these strategies. STRATEGIES FOR CHANGE:The project engaged AH managers, clinical educators and clinicians from across the region to collaboratively develop and implement the identified professional support strategies. EFFECTS OF CHANGE:Access to professional support and building the capacity of the workforce improved through shared approaches including the following: clinical supervision, professional shadowing and peer support for educators and shared student placements. LESSONS LEARNT:Benefits to using a regional approach to plan, deliver and evaluate professional support for AH were identified. Recommendations are made to inform collaborative approaches to professional support in regional settings.

    2026The Australian journal of rural health(2026)
    引用
    AI阅读
    加入学术空间
    4Assessment and Use of Electronic Patient Records for Smoking Cessation Support in Hospital Setting: A Cross-Sectional Study.
    Stephen Barrett, Gabrielle Barrett, Tim Milroy

    ISSUE ADDRESSED:Tobacco use remains a leading cause of preventable illness and death. Hospital admissions offer a critical opportunity to support smoking cessation. Electronic patient record (ePR) systems can enable systematic identification and coordination of cessation care; however, clinician engagement with smoking-related ePR functionality is not well understood. This study examined smoking-related assessment and documentation practices, and determinants influencing use of the ePR for smoking cessation support in a regional Australian hospital. METHODS:A cross-sectional survey was distributed to clinicians working on inpatient wards. The survey assessed how often clinicians asked about smoking, what information they collected and documented, and clinicians' knowledge and use of ePR functionality to support cessation. Barriers and enablers were explored using the NASSS (Non-adoption, Abandonment, Scale-up, Spread, Sustainability) framework, which considers technology use across clinical, organisational and system levels. RESULTS:Of the 101 respondents, 93% reported routinely asking about smoking status. However, only 50% indicated that they knew how to identify smoking status within the ePR, and fewer than 20% reported confidence in using the system to assess nicotine dependence or provide structured cessation support. Only 6% had received relevant training. Reported barriers included lack of knowledge, limited training, low system usability and competing priorities within workflows. CONCLUSIONS:While most clinicians ask about smoking, effective use of the ePR to deliver comprehensive cessation support remains limited. SO WHAT?: Improving smoking cessation support in hospital settings requires more than clinician intent. Training, embedded decision support and better system integration are needed to close the gap between clinical opportunity and evidence-based care.

    2026Health promotion journal of Australia official journal of Australian Association of Health Promotio...(2026)
    引用
    AI阅读
    加入学术空间
    5Navigating Complex Care: A Case Study on Lessons Learnt in Early-Onset Dementia in an Acute Older Adult Mental Health Admission
    Bec Beesley, Melbin Kottarathil Joy, Jordie Hodson
    2026INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 573 篇论文

    合作机构(100)

    莫纳什大学合作论文 107
    墨尔本大学合作论文 93
    乐卓博大学合作论文 73
    奥斯汀健康合作论文 56
    Eastern Health合作论文 43
    Monash Health合作论文 41
    Western Health合作论文 35
    Barwon Health合作论文 33
    Alfred Health合作论文 29
    迪肯大学合作论文 26

    机构统计